Today Stories

Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation OSE Immunotherapeutics to receive an upfront payment of $48 million and will be eligible to receive up to an additional $665 million in milestone payments NORTH CHICAGO, Ill. and NANTES, France, Feb. 28, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, today announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage. OSE-230 is a first-in-class monoclonal antibody designed to activate ChemR23, a G-Protein Coupled Receptor (GPCR)…

Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. “We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. “By strengthening and further diversifying our oncology pipeline beyond I-O, we will unlock exciting opportunities that support BMS’s…

Mr. Johnson Brings Over 35 Years of Financial and Operating Experience to Leadership Team DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced that Philip Johnson has been appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024. Mr. Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023.  Mr. Johnson joins Jazz Pharmaceuticals with over 35 years of financial experience, most recently leading Eli Lilly and Company's treasury and investor relations operations as Group Vice President of Finance. In his new role, Mr. Johnson will oversee financial reporting, accounting, tax, treasury, risk management, financial planning and analysis, information ser…

Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) Seeks Global Research and Technology Talent to Form New Startup Focused on: “AI/ML Platform for Targeting RNA with Small Molecules“ REHOVOT, Israel and HEIDELBERG, Germany, February 20, 2024. AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its latest global call for applications to identify computational biologists, biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel. AION Labs’ next startup will focus on the developm…

AstraZeneca announced today the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. As a result of the acquisition, Icosavax has become a subsidiary of AstraZeneca, with operations in Seattle, US. The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12. IVX-A12 is a potential first-in-class, Phase III-ready, combination protein VLP vaccine which targets both RSV and human metapneumovirus (hMPV), two leading causes of severe res…

Pharma and biotech customers distinguish excellence in capabilities, compatibility, expertise, quality and reliability WALTHAM, Mass.--(BUSINESS WIRE)-- For the 11th consecutive year, Thermo Fisher Scientific’s pharma and biopharma customers recognized its contract manufacturing excellence through the annual CDMO Leadership awards sponsored by Outsourced Pharma and Life Science Connect. Thermo Fisher received five awards for capabilities, compatibility, expertise, and quality and reliability from three customer groups: big pharma, small pharma, and both. In total, customers evaluated 98 companies across 23 performance metrics for these honors, which distinguish the top contract manufacturing organizations by surveying leading global pharma and biotech companies. That research, based on the…

New Thermo Scientific Dionex Inuvion Ion Chromatography System streamlines ion analysis and expands analytical testing capabilities for ionic and small polar compounds WALTHAM, Mass.--(BUSINESS WIRE)-- To support a wider range of ion chromatography analysis with one instrument, Thermo Fisher Scientific Inc., today launched the Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis. beverage labs with the necessary equipment to determine ionic contaminants in water. The technology also helps ident…

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. As previously announced,1 the acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma. AIO-001 could expand GSK’s respiratory biologics portfolio to potentially reach the 40% of severe asthma patients with low T2 inflammation (a type of overactive immune response associated with asthma).2 AIO-001 has the potential to be administered every six months due to its high po…

PPD clinical research business provides lab customers a comprehensive solution to help ensure safe medicines for patients WILMINGTON, N.C.--(BUSINESS WIRE)-- The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, is adding mycoplasma and additional biosafety testing capabilities to its expanding portfolio of services at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. This new service, offered by the analytical testing service of the clinical research business, ensures biopharmaceutical products are free of contaminants, helping customers deliver safe medicines for patients. “The continuing expansion of our GMP lab to include these new services further strengthens our ability to help our customers make the world healthie…

-- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024 -- -- Seladelpar Phase 3 Data Demonstrates a Best-in-Disease Profile for Second-Line PBC -- -- Acquisition Expands Gilead’s Long-Standing Commitment to Patients with Liver Diseases -- FOSTER CITY, Calif. & NEWARK, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC)…

The team will engineer cells to make membrane proteins efficiently The proteins will be used for drug discovery and screening, and as catalysts in sustainable chemical production The £1.8m Engineering Biology Mission Award has been given by UK Research and Innovation (UKRI) A team of academics from Aston University and the University of Warwick has secured a £1.8m grant to engineer microbial cell factories to produce membrane proteins which will support future drug screening and sustainable chemical production. Membrane proteins are crucial molecules on the surface of cells with numerous biological functions, such as sensing hormones or cell communication. The top ten selling medicines worldwide and multiple vaccines, including those for COVID-19, hepatitis B and whooping cough, target m…

Today, Boehringer Ingelheim and CBmed GmbH Center for Biomarker Research in Medicine (CBmed) announced a long-term strategic partnership. Jointly the partners will apply translational medicine approaches to accelerate the development of first-in-class medicines to transform the lives of people with cancer and achieve Boehringer’s ultimate ambition to cure a range of cancers. Precision medicine has revolutionized cancer care, offering great potential to cure more types of cancer. Still, 97 out of every 100 clinical trials testing compounds in a specific indication fail to demonstrate significant benefit for cancer patients.1 The reason is often a poor understanding of how or why a cancer treatment kills cancer cells directly or via activation of the immune system and which cancer patient…

CAMBRIDGE, MA / ACCESSWIRE / February 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Stéphane Bancel, Chief Executive Officer, has been elected to the National Academy of Engineering (NAE), broadly known as one of the highest acknowledgments of achievement in the field, in recognition of distinguished contributions to engineering and the "development and manufacturing of pharmaceutical products, including the COVID-19 vaccine." Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna's board of directors since March 2011. In the 13 years since he joined Moderna, Mr. Bancel has led the company from startup to global commercial enterprise. Today, the Company has 45 mRNA therapeutic and vaccine programs in its pipeline, nine of…

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to the Fortune® World's Most Admired Companies™ list for the seventh consecutive year. For the third year in a row IQVIA earned the first-place ranking within the Health Care: Pharmacy and Other Services category. The company also ranked number one in six categories for quality of management, people management, innovation, quality of products and services, global competitiveness, and use of corporate assets. Fortune® World's Most Admired Companies™ is the definitive report card on corporate reputation. Since 1997, Fortune® has identified, selected, and ranked the World’s Most Admi…

The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes™” aims to enhance awareness of and access to cancer screening, clinical trials and support in medically underrepresented communities across the United States ATLANTA & NEW YORK--(BUSINESS WIRE)-- The American Cancer Society (ACS) and Pfizer Inc. (NYE: PFE) today announced the launch of “Change the Odds: Uniting to Improve Cancer Outcomes™,” a three-year initiative to bridge the gap in cancer care disparities. Through $15 million in funding from Pfizer, the initiative aims to improve health outcomes in medically underrepresented communities across the United States by enhancing awareness of and access to cancer screenings, clinical trial opportunities, and patient support and comprehensive navigation. “Change the Odds”…

Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses Paris, February 5, 2024. Sanofi today launches ‘Cancer & Work: Acting Together’, a global program to support Sanofi employees whose lives are impacted by cancer and other critical illnesses. This program covers all Sanofi employees in the world if they are diagnosed with cancer or critical illnesses*. It provides social, emotional and financial support and secures the job, salary and benefits of any employee for up to twelve months, no matter the role or geographical location. Natalie BickfordChief People Officer, Sanofi“Many of us will face cancer one way or another in our lives. The last thing you want to be thinking about when you are di…

BURLINGTON, N.C., Feb. 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine's list of the World's Most Admired Companies™, a recognition of the most respected and reputable companies globally. "Labcorp is honored to be included on this year's FORTUNE World's Most Admired Companies list," said Adam Schechter, chairman and CEO of Labcorp. "This recognition is a testament to the hard work and dedication of Labcorp employees who work tirelessly to help address some of the world's most important health challenges and support our mission to improve health and improve lives." The annual survey designated Labcorp as one of only five companies to attain Most Admired status in the "Health Care:…

Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million) London, UK, 1 February 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B financing round. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, and the addition of three new investors – NEVA SGR (the venture capital arm of Intesa Sanpaolo banking group), LIFTT (the venture capital focused on deep-tech chaired by Stefano Buono) and Simon Fiduciaria (the fiduciary company of Ersel Group)…

The 38th PM Society Awards will take place on Friday 15th March in London with Twist Health as the headline sponsor. They are the longest running and largest awards event in the pharma marketing and healthcare agency calendar. To view all the finalist agencies and clients, please visit the PM Society’s website. Where: JW Marriott Grosvenor House LondonWhen: Friday 15th March 2023Time: 12:00pm - 8:00pmDress code: Semi Formal The awards attract around 1000 guests, showcases the best creative work our industry has to offer and gives an opportunity for attendees to network and celebrate! Buy your tickets now and also enjoy:• An exciting digital exhibition before the awards ceremony• Networking with your colleagues, clients and teams• Three-course meal with wine• Top comedy talent  For more inf…

– New Median Turnaround Time from Leukapheresis to Product Release in U.S. Anticipated to be Reduced from 16 Days to 14 Days – – Continues to Support Kite’s Industry-Leading Overall Turnaround Time and Reliability – – Time to Treatment is a Critical Factor for CAR T-cell Therapy Patients – SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated to be reduced from 16 days to 14 days. Median TAT is defined as time from leukapheresis, when a patient’s T cells are collected, to product release; manu…